2017
Observational study in comorbid patients with CLL receiving first-line rituximab-bendamustine
ŠPAČEK, M., P. OBRTLÍKOVÁ, Markéta HADRABOVÁ, Eduard CMUNT, J. KARBAN et. al.Basic information
Original name
Observational study in comorbid patients with CLL receiving first-line rituximab-bendamustine
Authors
ŠPAČEK, M. (203 Czech Republic), P. OBRTLÍKOVÁ (203 Czech Republic), Markéta HADRABOVÁ (203 Czech Republic, belonging to the institution), Eduard CMUNT (203 Czech Republic), J. KARBAN (203 Czech Republic), J. MOLINSKÝ (203 Czech Republic), M. SIMKOVIC (203 Czech Republic), Heidi MÓCIKOVÁ (703 Slovakia, belonging to the institution), L. MOHAMMADOVA (203 Czech Republic), Anna PANOVSKÁ (203 Czech Republic, belonging to the institution), J. NOVÁK (203 Czech Republic), Lukáš SMOLEJ (203 Czech Republic), Michael DOUBEK (203 Czech Republic, belonging to the institution) and Marek TRNĚNÝ (203 Czech Republic)
Edition
XVII International Workshop on Chronic Lymphocytic Leukemia, 2017
Other information
Language
English
Type of outcome
Conference abstract
Field of Study
10606 Microbiology
Confidentiality degree
is not subject to a state or trade secret
RIV identification code
RIV/00216224:14110/17:00099491
Organization unit
Faculty of Medicine
Keywords in English
observational; CLL; study
Changed: 14/2/2018 14:58, Bc. Kateřina Kolesová
Abstract
V originále
Observational study in comorbid patients with CLL receiving first-line rituximab-bendamustine, Observational study in comorbid patients with CLL receiving first-line rituximab-bendamustine
Links
| 692298, interní kód MU |
|